AstraZeneca said Tuesday a new formulation of its blockbuster heartburn treatment Nexium has won FDA approval.
Like its capsule counterpart, the new delayed-release oral suspension version of Nexium is designed to treat gastroesophageal reflux disease and reduce the risk of non-steroidal anti-inflammatory drug associated stomach ulcers, AstraZeneca said.
“Some patients with acid-related diseases have difficulties swallowing their oral medication when it is a solid pill,” said Nexium development leader Doug Levine in a statement. “This new prescription option to swallow an oral suspension of Nexium, or to have it administered via a stomach tube, provides patients with an alternative method of administration.”
Nexium was the third best-selling global prescription drug brand for 2005, with sales of $5.7 billion, according to figures from IMS Health.
Nexium was also third best in the US prescription drug market during 2005, with sales of $4.2 billion.
The new Nexium formulation will be available in the first quarter of 2007, AstraZeneca said.
This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.